

# 1 **Saliva swabs are the preferred sample for Omicron**

## 2 **detection**

3

4 Gert Marais<sup>1</sup>, Nei-yuan Hsiao<sup>2</sup>, Arash Iranzadeh<sup>2</sup>, Deelan Doolabh<sup>2</sup>, Annabel Enoch<sup>3</sup>

5 Chun-yat Chu<sup>1</sup>, Carolyn Williamson<sup>2</sup>, Adrian Brink<sup>1</sup>, Diana Hardie<sup>2,\*</sup>

6

7 <sup>1</sup>Department of Medical Microbiology, University of Cape Town, Cape Town, South

8 Africa

9 <sup>2</sup>Department of Medical Virology, University of Cape Town, Cape Town, South Africa

10 <sup>3</sup>Green Point Diagnostic Virology Laboratory, National Health Laboratory Service,

11 Cape Town, South Africa

12

13 \*Corresponding author

14 Email: [diana.hardie@uct.ac.za](mailto:diana.hardie@uct.ac.za)

15

16

17 **Abstract**

18

19 The Omicron variant is characterised by more than 50 distinct mutations, the majority  
20 of which are located in the spike protein. The implications of these mutations for  
21 disease transmission, tissue tropism and diagnostic testing are still to be determined.

22 We evaluated the relative performance of saliva and mid-turbinate swabs as RT-  
23 PCR samples for the Delta and Omicron variants. The positive percent agreement  
24 (PPA) of saliva swabs and mid-turbinate swabs to a composite standard was 71%  
25 (95% CI: 53-84%) and 100% (95% CI: 89-100%), respectively, for the Delta variant.

26 However, for the Omicron variant saliva and mid-turbinate swabs had a 100% (95%  
27 CI: 90-100%) and 86% (95% CI: 71-94%) PPA, respectively. This finding supports  
28 ex-vivo data of altered tissue tropism from other labs for the Omicron variant.

29 Reassessment of the diagnostic testing standard-of-care may be required as the

30 Omicron variant become the dominant variant worldwide.

## 31 **Introduction**

32

33 SARS-CoV-2 variants are characterised by distinct mutations which impact on  
34 disease transmissibility, immune escape, diagnostics and possibly tissue tropism.  
35 Omicron, in particular, has an extraordinary number of mutations, with at least 50  
36 mutations across the genome, 30 of which are located in the spike protein and 15 in  
37 the receptor binding domain.<sup>1</sup> While functional change in terms of receptor binding is  
38 currently to be elucidated, the pattern of viral shedding and resulting impact on  
39 diagnostic sampling methods is currently unknown.

40

## 41 **Methods**

42

43 As part of an on-going study<sup>2</sup> to evaluate the diagnostic performance of different  
44 sample types, we recruited 382 acutely symptomatic, non-hospitalised patients who  
45 presented for SARS-CoV-2 testing between August and December 2021 at the  
46 Groote Schuur Hospital COVID testing centre in Cape Town. Paired mid-turbinate  
47 (MT) and saliva (SA) swabs were collected and tested by RT-PCR (Supplementary  
48 methods).

49

50 Samples were classified as Omicron or Delta based on whole genome sequencing  
51 data, diagnostic PCR target failures and sampling date (Supplementary  
52 methods).<sup>1,3,4</sup> A composite standard for SARS-CoV-2 infection was used for  
53 comparison of sample types, with infection considered present if SARS-CoV-2 RNA  
54 was detected on either the MT or matched SA swab.

55

## 56 **Results**

57

58 The positive percent agreement (PPA) of SA swabs and MT swabs to this standard  
59 was 71% (95% CI: 53-84%) and 100% (95% CI: 89-100%), respectively, for the  
60 Delta variant. This was similar to our previous findings for the Beta variant.<sup>2</sup>

61 However, for the Omicron variant SA and MT swabs had a 100% (95% CI: 90-100%)  
62 and 86% (95% CI: 71-94%) PPA, respectively (Supplementary Figure 1). The mean  
63 RT-PCR cycle threshold differences between MT and SA, using the nucleocapsid  
64 gene target as a reference, were 5.2 (SD  $\pm$  5.1,  $P < 0.0001$ ) and 1.5 (SD  $\pm$  5.9,  
65  $P = 0.18$ ) for Delta and Omicron respectively. The median time from symptom onset to  
66 positive test for Delta and Omicron assigned cases was 3 days (range: 1-10) and 2  
67 days (range: 0-7).

68

## 69 **Conclusion**

70

71 These findings suggest that the pattern of viral shedding during the course of  
72 infection is altered for Omicron with higher viral shedding in saliva relative to nasal  
73 samples resulting in improved diagnostic performance of saliva swabs. This supports  
74 the ex-vivo finding of improved viral replication in upper respiratory tract tissue and  
75 possibly altered tissue tropism.<sup>5</sup> This is an important finding as the current standard  
76 of care for diagnosis using swabs of the nasal or nasopharyngeal mucosa may be  
77 suboptimal for the Omicron variant.

78

79

## 80 **References**

81

82 1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-  
83 CoV-2 Omicron variant in southern Africa. medRxiv 2021:2021.12.19.21268028.

84 2. Chu CY, Marais G, Opperman C, et al. Performance of saliva and mid-  
85 turbinate swabs for detection of the beta variant in South Africa. The Lancet  
86 Infectious Diseases 2021.

87 3. Valley-Omar Z, Marais G, Iranzadeh A, et al. Reduced amplification efficiency  
88 of the RNA-dependent-RNA-polymerase (RdRp) target enables tracking of the Delta  
89 SARS-CoV-2 variant using routine diagnostic tests. medRxiv  
90 2021:2021.10.01.21264408.

91 4. Scott L, Hsiao N-y, Moyo S, et al. Track Omicron's spread with molecular  
92 data. Science Commentary 2021:eabn4543.

93 5. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta  
94 in human bronchus but with less severe infection in lung. 2021. (Accessed 16  
95 December 2021, at [https://www.med.hku.hk/en/news/press/20211215-omicron-sars-  
96 cov-2-  
97 infection?utm\\_medium=social&utm\\_source=twitter&utm\\_campaign=press\\_release.](https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection?utm_medium=social&utm_source=twitter&utm_campaign=press_release))

98

99

## 100 **Acknowledgements**

101

102 This research was funded in whole, or in part, by Wellcome [203135/Z16/Z]. For the  
103 purpose of Open Access, the author has applied a CC BY public copyright licence to  
104 any Author Accepted Manuscript version arising from this submission.

105

106 Testing was conducted at the Groote Schuur Hospital and Green Point National  
107 Health Laboratory Service diagnostic virology laboratories.

108

## 109 **Ethics statement**

110

111 This research has been approved by the University of Cape Town Human Research  
112 Ethics Committee (Ref: 420/2020).

113


## 114 **Conflict of interests**

115

116 The authors declare no conflict of interest

117 **Figures**

118



119

120 **Figure 1.** The cycle threshold (Ct) or cycle number (CN) values for paired mid-  
121 turbinate (MT) and saliva (SA) swabs are shown for Delta and Omicron variant  
122 positive samples. Paired samples were tested on the same diagnostic platform on  
123 the same day and samples where only the MT or SA swab was positive were  
124 excluded from the analysis. The nucleocapsid (N) gene Ct value was used for  
125 analysis if the sample was tested with the Allplex™ 2019-nCoV assay (Seegene,  
126 South Korea). This was because the Delta and Omicron variants are not associated  
127 with N gene target failure and other assays used also target the N gene. Statistical

128 analysis consisted of paired t-tests performed using GraphPad Prism version 9.3.0  
129 for macOS, GraphPad Software, San Diego, California USA, [www.graphpad.com](http://www.graphpad.com).  
130 The bar represents the mean Ct value with error bars showing 1 standard deviation.  
131 ns: not significant. \*\*\*\*: P value < 0.0001.  
132



## 133 **Supplementary methods**

134

### 135 **Swab collection**

136

137 Swabs were self-collected by the study participants under supervision of a  
138 healthcare worker.

139

140 Participants should not have had any food, drink, tobacco or gum in the 30 minutes  
141 preceding saliva swab collection. Participants were initially instructed to cough 3-5  
142 times, covering their mouths with the inner elbow. They were then asked to swab on  
143 the inside of both cheeks, above and below the tongue, on the gums and hard  
144 palate. A minimum swabbing duration of 30 seconds was required. The swab was  
145 transported in a sealed container to the laboratory without any transport media.

146

147 Mid-turbinate swabs were collected by a healthcare worker. The swab was inserted  
148 2-3 cm into each nostril and transported in a sealed container to the laboratory  
149 without any transport media.

150

151 On arrival in the laboratory, all swabs were placed in 2 ml Sarstedt containers with  
152 1.5 ml of sterile autoclaved 0.9% saline in preparation for downstream RT-PCR  
153 testing.

154

### 155 **RT-PCR**

156

157 Swabs were tested by the Groote Schuur Hospital National Health Laboratory  
158 Service (NHLS) diagnostic virology laboratory in Cape Town, South Africa. The  
159 assays in used by this laboratory during the study period were the Allplex™ 2019-  
160 nCoV assay (Seegene, South Korea) (n=343), the Abbott RealTime SARS-CoV-2  
161 assay (Abbott Laboratories, USA) (n=7) and the Abbott Alinity m SARS-CoV-2 assay  
162 (Abbott Laboratories, USA) (n=32). The assay used was based on laboratory  
163 operational requirements and no study-specific considerations or requirements were  
164 in place. The Abbott assay were run as per kit package inserts and subject to the  
165 operational requirements of a South African National Accreditation System (SANAS)  
166 accredited diagnostic virology laboratory. The Seegene assay was run with an in-  
167 house developed laboratory-specific sample processing technique which was subject  
168 to a validation as per SANAS requirements. Paired samples were in all cases tested  
169 using the same RT-PCR platform.

170

171 Selected samples (n=31) that tested positive primarily were assessed for Spike gene  
172 target failure using the TaqPath COVID-19 CE-IVD RT-PCR Kit (Thermo Fisher  
173 Scientific, USA) at the Green Point NHLS diagnostic virology laboratory.

174

### 175 **Variant classification**

176

177 A confirmed classification as Delta or Omicron was based on whole genome  
178 sequencing as previously described.<sup>1</sup> A probable assignment was based on variant-  
179 specific RT-PCR gene target failure profiles noted during diagnostic testing<sup>3,4</sup> and a  
180 possible assignment was based on the local dominant circulating variant at the time  
181 of sample collection.<sup>1</sup> RNA-dependent RNA-polymerase (RdRp) gene target failure

182 (R-GTF) was considered present if the RdRp Ct value was >3.5 cycles greater than  
183 the Envelope (E) gene Ct value. In cases where the RdRp gene was not detected,  
184 R-GTF was considered present if the E gene had a Ct value of <30. Spike (S) gene  
185 target failure was considered present if all assay SARS-CoV-2 gene targets other  
186 than S were detected. The Delta variant was dominant in Cape Town prior to the 19<sup>th</sup>  
187 of November 2021 and the Omicron variant subsequently (Supplementary Figure  
188 1).<sup>1</sup> For the purposes of positive percent agreement, negative percent agreement,  
189 positive predictive value and negative predictive value calculation a Delta or Omicron  
190 possible, probable or confirmed classification was accepted.

191



192

193 **Supplementary figures**

194

A

Sample type and SARS-CoV-2 lineage	Positive percent agreement	95% CI	Negative percent agreement	95% CI	Positive predictive value	95% CI	Negative predictive value	95% CI
Midturbinate swab - Omicron	86	71-94	100	91-100	100	89-100	88	76-95
Saliva swab - Omicron	100	90-100	100	91-100	100	90-100	100	91-100
Midturbinate swab - Delta	100	89-100	100	99-100	100	89-100	100	99-100
Saliva swab - Delta	71	53-84	100	99-100	100	85-100	97	94-98



195

196 **Supplementary Figure 1.** (A) Table showing the positive and negative percent  
 197 agreement and positive and negative predictive values for mid-turbinate and saliva  
 198 swabs with 95% confidence intervals shown. Confidence intervals were calculated  
 199 using the Wilson-Brown method using GraphPad Prism version 9.3.0 for macOS,

200 GraphPad Software, San Diego, California USA, [www.graphpad.com](http://www.graphpad.com). For the Delta  
201 variant, 277 samples tested negative, for 22 samples both the saliva (SA) and mid-  
202 turbinate (MT) swab tested positive and for 9 samples only the MT swab tested  
203 positive. No samples tested SA swab positive only. For the Omicron variant, 38  
204 samples tested negative, for 31 samples both the SA and MT swab tested positive  
205 and for 5 samples only the SA swab tested positive. No samples tested MT swab  
206 positive only. (B) The proportions of SARS-CoV-2 lineage assignments by listed  
207 criteria for samples testing positive are shown. 36 samples were classified as  
208 Omicron, 75% as probable due to S gene target failure during diagnostic testing,  
209 17% as possible due to the dominant circulating variant at the time of sample  
210 collection and 8% as confirmed by whole genome sequencing. Similarly, 31 samples  
211 were classified as Delta, 74% as probable due to RdRp gene target failure during  
212 diagnostic testing, 23% as possible due to the dominant circulating variant at the  
213 time of sample collection and 3% as confirmed by whole genome sequencing. (C)  
214 The longitudinal proportion of Pangolin lineages for samples originating in the  
215 Western Cape, South Africa.